ICoN-1 Phase 3 Study of the Efficacy and Safety of Treatment With MNKD-101, Clofazimine Inhalation Suspension
Study sponsor: Mannkind Corporation
Primary completion is the date data collection ends for the main study measures, not when results are published.
Primary completion2025-11-10Actual
Enrollment · participants132Actual
Source updated2025-11-12Last update listed in the registry record
No recorded changes are available for this view and time period. Our history may be incomplete; this does not establish that the trial stayed unchanged.